INFO & CONTACTS:  +39 02 2390 1

A Phase 1b/2, multicenter, open-label study to evaluate the efficacy and safety of GSK5764227, alone or in combination with other treatments, in participants with previously treated, unresectable, or metastatic advanced gastrointestinal cancer (223675 Study)

Phase: Phase I-II clinical trials

Principal Investigator: Dott. Pietrantonio Filippo

Main Facility: Oncologia Medica Gastroenterologica

Drug: GSK5764227 (experimental drug)

Pathologies: Colorectal cancer (CRC), Pancreatic cancer

ClinicalTrials.gov: Read the details about clinical trials

This is an open-label study, and participants will be assigned to separate groups based on their gastrointestinal cancer type (called Cohorts).

The study will have two groups: participants with colorectal cancer (Cohort A) and those with PDAC (Cohort B). Cohort A is composed of two subcohorts: CRC-A and CRC-B. Each cohort and subcohort includes two parts: Part 1A or 1B and Part 2A or 2B. In Cohort A (Part 1A), participants will be randomly assigned to test two doses of GSK5764227 for each subcohort – every three weeks (CRC-A) or every two weeks (CRC-B).

Part 2A will further evaluate the safety and efficacy of GSK5764227, alone and/or in combination with other standard treatments such as chemotherapy. In Cohort B (Part 1B), participants will receive a single dose of GSK5764227 every three weeks. Additionally, Part 2B will explore how well the treatment works and its safety, alone and/or in combination with other treatments.

The primary objective of this study is to evaluate how well GSK5764227 works in treating cancer in participants with advanced, inoperable CRC (Part 1A [CRC]) and advanced, inoperable PDAC (Part 1B [PDAC]).

The secondary objectives for Part 1A and Part 1B are:

• To evaluate other measures of GSK5764227's effectiveness in fighting cancer (clinical activity).

• To evaluate the side effects reported by participants treated with

GSK5764227 and its tolerability as a treatment.

• Monitor GSK5764227 levels in the body after administration via intravenous drip.

• Assess whether GSK5764227 triggers an immune response.

Last update: 14/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe